{"entity":{"id":"nct04306224","kind":"trial","name":"A Study of IMC-002 in Subjects With Metastatic or Locally Advanced Solid Tumors and Relapsed or Refractory Lymphomas","aka":[],"tldr":"A phase 1 trial of IMC-002 run by ImmuneOncia Therapeutics Inc., completed.","summary":"A Study of IMC-002 in Subjects With Metastatic or Locally Advanced Solid Tumors and Relapsed or Refractory Lymphomas is a phase 1 interventional study registered as NCT04306224 by ImmuneOncia Therapeutics Inc., with 12 participants enrolled, started 2020-06-05. Conditions recorded: Solid Tumor and Lymphoma. Interventions recorded: IMC-002.","status":"completed","asOf":"2026-11-03","links":[{"label":"ClinicalTrials.gov NCT04306224","url":"https://clinicaltrials.gov/study/NCT04306224"}],"tags":["pipeline","ctgov-ingest"],"related":[],"cancers":["metastatic-cancer","non-hodgkin-lymphoma"],"sections":[],"technologies":[],"targets":[],"drugs":["imc-002"],"companies":["immuneoncia-therapeutics"],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"nct":"NCT04306224","phase":"1","setting":"A First-in-Human, Open-Label, Multiple-Ascending Dose Study to Investigate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Clinical Activity of IMC-002 in Subjects With Metastatic or Locally Advanced Solid Tumors and Relapsed or Refractory Lymphomas","sponsor":"ImmuneOncia Therapeutics Inc.","enrolled":12,"enrolledBasis":"registry","outcomes":[]},"route":"/trials/nct04306224/","neighbours":{"cancer":[{"id":"metastatic-cancer","kind":"cancer","name":"Metastatic cancer (cancer that has spread)","route":"/cancers/metastatic-cancer/"},{"id":"non-hodgkin-lymphoma","kind":"cancer","name":"Non-Hodgkin lymphoma (all types)","route":"/cancers/non-hodgkin-lymphoma/"}],"drug":[{"id":"imc-002","kind":"drug","name":"IMC-002","route":"/drugs/imc-002/"}],"company":[{"id":"immuneoncia-therapeutics","kind":"company","name":"ImmuneOncia Therapeutics","route":"/companies/immuneoncia-therapeutics/"}]}}